Study reveals 5.05 percent of individuals carry pathogenic/likely pathogenic variants in in large, unselected U.S. population.

Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan (Welireg) for the treatment of renal cell carcinoma.

Lower risk for MCI and dementia also seen with moderate, high cardiovascular health in those with high polygenic risk score.

Belimumab is linked to a reduced risk for all-cause mortality compared with azathioprine, methotrexate, and mycophenolate among patients with nonrenal SLE.

Akebia Therapeutics has decided not to initiate a clinical trial assessing vadadustat in patients with late-stage CKD not on dialysis.

Investigators analyzed exfoliated cells in urine test specimens to identify 50 candidate RNAs for prostate cancer detection.

Topline data were announced from a phase 3 trial evaluating obinutuzumab in adults with systemic lupus erythematosus on standard therapy.

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

(HealthDay News) — The U.S. Food and Drug Administration (FDA) has recalled over half a million bottles of a widely prescribed blood pressure medication, prazosin hydrochloride, because of concerns ...

The Interaktor app was well-received by patients undergoing radiotherapy for prostate cancer seeking to monitor and manage their symptoms.The effectiveness of the Interaktor app was evaluated in a ...

(HealthDay News) — Adolescents whose parents had two or more opioid prescriptions have a more than doubled risk for persistent opioid use, according to a study published online Oct. 23 in PLOS ...

Michael Liu, M.D., from Beth Israel Deaconess Medical Center in Boston, and colleagues conducted a cross-sectional study to examine the percentage of U.S. health care professionals (HCPs) sponsored ...